Evidence map›Paper›PMID 39915126›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Safety, Dosimetry, and Feasibility of [

Liza Lindenberg, Thomas A Hope, Frank I Lin, Steven P Rowe, Darko Pucar, Noella Gilbert, Daniela Chicco, Beilei He, Benedikt Feuerecker, Elena Castaldi and 1 more

Abstract readMulticenter StudyClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Safety, Dosimetry, and Feasibility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Liza LindenbergMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Thomas A HopeUniversity of California, San Francisco, California.
Frank I LinMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Steven P RoweMolecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Darko PucarYale University, New Haven, Connecticut.
Noella GilbertNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Daniela ChiccoAdvanced Accelerator Applications, a Novartis Company, Turin, Italy.
Beilei HeNovartis Pharma AG, Basel, Switzerland.
Benedikt FeuereckerNovartis Pharma AG, Basel, Switzerland.
Elena CastaldiAdvanced Accelerator Applications, a Novartis Company, Turin, Italy.
Lilja B SolnesDivision of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland lsolnes1@jhmi.edu.

Funding

MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA235741
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in most prostate cancers (PCs). PET and CT imaging studies using

Indexed as

Prostatic NeoplasmsSafetyAgedAged, 80 and overFeasibility StudiesGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyRadiometryRecurrenceTissue DistributionGallium-68gallium 68 PSMA-11Gallium IsotopesGallium Radioisotopes68Ga-PSMA-R2dosimetryPETprostate cancerPSMA

Identifiers

PMID39915126
PMCPMC11876733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.